What are the effects of Cushing's syndrome (Hyperadrenocorticism), a condition characterized by excess cortisol (Corticosteroid) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Cushing's syndrome, characterized by excess cortisol levels, has severe effects on morbidity, mortality, and quality of life, including weight gain, hypertension, diabetes, and mood disturbances, and requires prompt treatment to prevent serious complications. The effects of Cushing's syndrome can be managed with medical therapies, such as metyrapone or ketoconazole, to reduce the cortisol burden, as recommended by the consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence 1.

Symptoms and Diagnosis

The symptoms of Cushing's syndrome include weight gain with central obesity, moon face, buffalo hump, purple striae, thin skin, easy bruising, muscle weakness, hypertension, diabetes, and mood disturbances. Diagnosis involves measuring cortisol levels through 24-hour urinary free cortisol, late-night salivary cortisol, overnight dexamethasone suppression test, and determining the source through ACTH levels, imaging studies, and possibly inferior petrosal sinus sampling.

Treatment

Treatment depends on the cause: surgical removal of tumors (transsphenoidal surgery for pituitary adenomas, adrenalectomy for adrenal tumors), radiation therapy, or medications like ketoconazole (400-1200 mg/day), metyrapone (250-750 mg every 4 hours), or mifeprone (300-1200 mg/day) to block cortisol production or effects 1. The use of metyrapone and ketoconazole should be limited to short-term treatment due to their adverse effects, such as hirsutism, dizziness, arthralgia, fatigue, hypokalaemia, and nausea, and the risk of hyperandrogenism and advanced bone age in children.

Complications

Chronic hypercortisolism can lead to serious complications, including cardiovascular disease, osteoporosis, and increased mortality, as highlighted in the scientific statement from the American Heart Association on resistant hypertension 1. Prompt treatment is crucial to prevent these complications and improve quality of life. The optimal antihypertensive regimen in patients with Cushing's syndrome remains to be adequately described, but adequate diuretic therapy, such as spironolactone or eplerenone, is likely a sensible strategy to block the mineralocorticoid actions of excess cortisol.

Management

The management of Cushing's syndrome requires a multidisciplinary approach, including endocrinologists, surgeons, and radiologists, to provide individualized treatment and prevent long-term complications. The goal of treatment is to normalize cortisol levels, control symptoms, and improve quality of life, while minimizing the risk of adverse effects and complications.

From the Research

Effects of Cushing's Syndrome

The effects of Cushing's syndrome, a condition characterized by excess cortisol levels, can be severe and life-threatening if left untreated 2, 3, 4, 5, 6.

Morbidity and Mortality

Untreated Cushing's syndrome results in substantial morbidity and mortality, making timely and effective treatment crucial 2.

Treatment Options

Treatment options for Cushing's syndrome include tumor-directed surgery, adrenally directed medical therapies, and other interventions such as radiotherapy and bilateral adrenalectomy 2, 3, 4, 5, 6.

Adrenally Directed Medical Therapies

Adrenally directed medical therapies, including ketoconazole, metyrapone, osilodrostat, mitotane, and etomidate, play a crucial role in managing Cushing's syndrome, particularly in patients with persistent or recurrent hypercortisolism postoperatively or those who cannot undergo tumor-directed surgery 2, 3, 4, 5, 6.

  • These medications inhibit one or several enzymes involved in adrenal steroidogenesis.
  • They differ in their mechanism of action, time course of pharmacologic effect, safety and tolerability, potential for drug-drug interactions, and route of administration.
  • Careful dose titration and patient monitoring are necessary to ensure safety and effectiveness while avoiding hypoadrenalism.

Severe Hypercortisolism

In cases of severe hypercortisolism, urgent therapeutic measures must be taken, and etiological investigation may be postponed until the patient is stabilized 4.

  • Adrenal steroidogenesis inhibitors, such as etomidate, ketoconazole, and metyrapone, are commonly used as first-line treatment for severe hypercortisolemia due to their rapid action and good efficacy and safety profile.
  • Other medications, such as mifepristone, may also be used, but their use is limited due to difficulties in monitoring efficacy and safety.

Key Considerations

Key considerations in the management of Cushing's syndrome include:

  • The need for careful patient monitoring and instruction to ensure treatment goals are met while minimizing adverse effects.
  • The importance of timely and effective treatment to prevent substantial morbidity and mortality.
  • The role of adrenally directed medical therapies in managing Cushing's syndrome, particularly in patients with persistent or recurrent hypercortisolism postoperatively or those who cannot undergo tumor-directed surgery.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Adrenally Directed Medical Therapies for Cushing Syndrome.

The Journal of clinical endocrinology and metabolism, 2021

Research

New prospects for drug treatment in Cushing disease.

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012

Research

Medical therapy in severe hypercortisolism.

Best practice & research. Clinical endocrinology & metabolism, 2021

Research

Pharmacological management of severe Cushing's syndrome: the role of etomidate.

Therapeutic advances in endocrinology and metabolism, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.